Enzalutamide: looking back at its preclinical discovery

Bibliography

• Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61:1079-92
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30
   PubMed Web of Science ®Google Scholar
• Huggins CB. Diagnosis and treatment of cancer of the prostate. Marquette Med Rev 1947;12:213-15
   PubMedGoogle Scholar
• Huggins C. Prostatic cancer treated by orchiectomy; the five year results. J Am Med Assoc 1946;131:576-81
   PubMed Web of Science ®Google Scholar
• Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 2013;32:5501-11
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Fleming MT, Hutson TE, et al. Trial design for metastatic castration-resistant prostate cancer. J Clin Oncol 2008;26:3647-8; author reply 8-9
   PubMed Web of Science ®Google Scholar
• Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68:4447-54
   PubMed Web of Science ®Google Scholar
• Marcelli M, Ittmann M, Mariani S, et al. Androgen receptor mutations in prostate cancer. Cancer Res 2000;60:944-9
   PubMed Web of Science ®Google Scholar
• Taplin ME, Bubley GJ, Shuster TD, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995;332:1393-8
   PubMed Web of Science ®Google Scholar
• Koivisto P, Kononen J, Palmberg C, et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997;57:314-19
   PubMed Web of Science ®Google Scholar
• Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995;9:401-6
   PubMed Web of Science ®Google Scholar
• Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12
   PubMed Web of Science ®Google Scholar
• Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26:242-5
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22
   PubMed Web of Science ®Google Scholar
• de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147-54
   PubMed Web of Science ®Google Scholar
• Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13:983-92
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138-48
   PubMed Web of Science ®Google Scholar
• Joung JY, Ha YS, Kim IY. Radium Ra 223 dichloride in castration-resistant prostate cancer. Drugs Today (Barc) 2013;49:483-90
   PubMed Web of Science ®Google Scholar
• Ha YS, Goodin S, DiPaola RS, et al. Enzalutamide for the treatment of castration-resistant prostate cancer. Drugs Today (Barc) 2013;49:7-13
   PubMed Web of Science ®Google Scholar
• Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787-90
   PubMed Web of Science ®Google Scholar
• Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375:1437-46
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97
   PubMed Web of Science ®Google Scholar
• Teutsch G, Goubet F, Battmann T, et al. Non-steroidal antiandrogens: synthesis and biological profile of high-affinity ligands for the androgen receptor. J Steroid Biochem Mol Biol 1994;48:111-19
   PubMed Web of Science ®Google Scholar
• Van Dort ME, Robins DM, Wayburn B. Design, synthesis, and pharmacological characterization of 4-[4, 4-dimethyl-3-(4-hydroxybutyl)-5-oxo-2-thioxo-1-imidazolidinyl]- 2-iodobenzonitrile as a high-affinity nonsteroidal androgen receptor ligand. J Med Chem 2000;43:3344-7
   PubMed Web of Science ®Google Scholar
• Xtandi (enzalutamide). Available from: https://www.xtandihcp.com/ [Last accessed 9 February 2014]
   Google Scholar
• Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002;20:3001-15
   PubMed Web of Science ®Google Scholar
• Tsao CK, Galsky MD, Small AC, et al. Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC). BJU Int 2012;110:1580-8
   PubMed Web of Science ®Google Scholar
• Sadar MD. Small molecule inhibitors targeting the “achilles’ heel” of androgen receptor activity. Cancer Res 2011;71:1208-13
   PubMed Web of Science ®Google Scholar
• Larson SM, Morris M, Gunther I, et al. Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 2004;45:366-73
   PubMed Web of Science ®Google Scholar
• Kelly WK, Slovin S, Scher HI. Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance. Urol Clin North Am 1997;24:421-31
   PubMed Web of Science ®Google Scholar
• Watson PA, Chen YF, Balbas MD, et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA 2010;107:16759-65
   PubMed Web of Science ®Google Scholar
• Li Y, Chan SC, Brand LJ, et al. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 2013;73:483-9
   PubMed Web of Science ®Google Scholar
• Guerrero J, Alfaro IE, Gomez F, et al. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer. Prostate 2013;73:1291-305
   PubMed Web of Science ®Google Scholar
• Balbas MD, Evans MJ, Hosfield DJ, et al. Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife 2013;2:e00499
   PubMed Web of Science ®Google Scholar
• Joseph JD, Lu N, Qian J, et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov 2013;3:1020-9
   PubMed Web of Science ®Google Scholar
• Nadiminty N, Tummala R, Liu C, et al. NF-kappaB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. Mol Cancer Ther 2013;12:1629-37
   PubMed Web of Science ®Google Scholar
• A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer (PREVAIL) (NCT01212991). Available from: http://clinicaltrials.gov/ct2/show/NCT01212991 [Last accessed 9 February 2014]
   Google Scholar
• Beer TM, Armstring AJ, Sternberg CN, et al. Enzalutamide in men with chemotherapy-naïve metastatic prostate cancer (mCRPC): results of phase 3 PREVAIL study. J Clin Oncol 2014;32(Suppl 4):abstract ID LBA1^
   Google Scholar
• A Study of MDV3100 Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer (NCT01288911). Available from: http://clinicaltrials.gov/ct2/show/NCT01288911 [Last accessed 9 February 2014]
   Google Scholar
• Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer (STRIVE) (NCT01664923). Available from: http://clinicaltrials.gov/ct2/show/NCT01664923 [Last accessed 9 February 2014]
   Google Scholar
• A Study to Test if MDV3100 is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy (NCT01302041). Available from: http://clinicaltrials.gov/ct2/results?term=NCT01302041 [Last accessed 9 February 2014]
   Google Scholar
• Study of MDV3100 as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer (NCT01547299). Available from: http://clinicaltrials.gov/ct2/results?term=NCT01547299 [Last accessed 9 February 2014]
   Google Scholar
• Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer (NCT01565928). Available from: http://clinicaltrials.gov/ct2/results?term=NCT01565928 [Last accessed 9 February 2014]
   Google Scholar
• A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients (NCT01650194). Available from: http://clinicaltrials.gov/ct2/show/NCT01650194 [Last accessed 9 February 2014]
   Google Scholar
• Efstathiou E, Titus M, Wen AS, et al. The effects of enzalutamide (ENZA) in combination with abiraterone acetate (AA) in patients with bone metastatic castration resistant prostate cancer (mCRPC) [abstract 2854]. Presented at: European Cancer Congress 2013; September 27 – October 1 2013; Amsterdam, The Netherlands
   Google Scholar
• Gucalp A, Tolaney S, Isakoff SJ, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res 2013;19:5505-12
   PubMed Web of Science ®Google Scholar
• Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer (NCT01597193). Available from: http://clinicaltrials.gov/ct2/results?term=NCT01597193 [Last accessed 9 February 2014]
   Google Scholar
• Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 2011;65:1180-92
   PubMed Web of Science ®Google Scholar
• Lee GT, Jung YS, Ha YS, et al. Bone morphogenetic protein-6 induces castration resistance in prostate cancer cells through tumor infiltrating macrophages. Cancer Sci 2013;104:1027-32
   PubMed Web of Science ®Google Scholar
• Dutt SS, Gao AC. Molecular mechanisms of castration-resistant prostate cancer progression. Future Oncol 2009;5:1403-13
   PubMed Web of Science ®Google Scholar
• Linja MJ, Savinainen KJ, Saramaki OR, et al. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001;61:3550-5
   PubMed Web of Science ®Google Scholar
• Shiota M, Yokomizo A, Naito S. Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target. J Mol Endocrinol 2011;47:R25-41
   Web of Science ®Google Scholar
• Culig Z, Hoffmann J, Erdel M, et al. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 1999;81:242-51
   PubMed Web of Science ®Google Scholar
• Hobisch A, Hoffmann J, Lambrinidis L, et al. Antagonist/agonist balance of the nonsteroidal antiandrogen bicalutamide (Casodex) in a new prostate cancer model. Urol Int 2000;65:73-9
   PubMed Web of Science ®Google Scholar
• Kawata H, Ishikura N, Watanabe M, et al. Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity. Prostate 2010;70:745-54
   PubMed Web of Science ®Google Scholar
• Jung ME, Ouk S, Yoo D, et al. Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). J Med Chem 2010;53:2779-96
   PubMed Web of Science ®Google Scholar
• Svensson C, Ceder J, Iglesias-Gato D, et al. REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer. Nucleic Acids Res 2014;42:999-1015
   PubMed Web of Science ®Google Scholar
• Lee GT, Kwon SJ, Lee JH, et al. Macrophages induce neuroendocrine differentiation of prostate cancer cells via BMP6-IL6 Loop. Prostate 2011;71:1525-37
   PubMed Web of Science ®Google Scholar